LIFAVYZE Trademark
Trademark Overview
On Friday, June 27, 2025, a trademark application was filed for LIFAVYZE with the United States Patent and Trademark Office. The USPTO has given the LIFAVYZE trademark a serial number of 99256149. The federal status of this trademark filing is REPORT COMPLETED SUSPENSION CHECK - CASE STILL SUSPENDED as of Monday, June 22, 2026. This trademark is owned by Bristol-Myers Squibb Company. The LIFAVYZE trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes
General Information
| Serial Number | 99256149 |
| Word Mark | LIFAVYZE |
| Filing Date | Friday, June 27, 2025 |
| Status | 654 - REPORT COMPLETED SUSPENSION CHECK - CASE STILL SUSPENDED |
| Status Date | Monday, June 22, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 27, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543
US |
Trademark Events
| Event Date | Event Description |
| Friday, June 27, 2025 | NEW APPLICATION ENTERED |
| Friday, June 27, 2025 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, November 5, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, November 17, 2025 | ASSIGNED TO EXAMINER |
| Tuesday, November 25, 2025 | SUSPENSION LETTER WRITTEN |
| Tuesday, November 25, 2025 | LETTER OF SUSPENSION E-MAILED |
| Tuesday, November 25, 2025 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Monday, June 22, 2026 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
